Sun Pharma growth engines stay firm as Organon integration raises leverage concerns

Investment View and Key Takeaways

In its August 2, 2026 result update, ICICI Direct Research retained its HOLD rating on Sun Pharmaceutical Industries and maintained a target price of Rs 2,090, compared with the CMP of Rs 1,990. The broker views Sun Pharma's domestic formulations and global innovative medicines businesses as continuing growth engines. However, investor attention is expected to remain focused on the proposed Organon acquisition and its integration.

ICICI Direct is cautiously optimistic, while noting that the acquisition's leverage and the relatively slower-growth portion of the acquired portfolio reduce the margin of safety.

Business Profile and Revenue Mix

Sun Pharma is described as the world's fourth-largest generics and specialty pharmaceutical company, with 43 manufacturing sites spanning specialty products, branded generics, complex generics, pure generics and APIs. The company is ranked number one in domestic formulations and has prescription leadership in 12 specialties.

In Q1 FY27, global innovative medicines accounted for around 22% of sales, principally in the US. The reported revenue mix was as follows:

Q1 FY27 Operating Performance

Reported Q1 FY27 revenue rose around 10% year-on-year to Rs 15,300 crore, supported by India, the global innovative portfolio, emerging markets and currency depreciation.

India formulations

India revenue grew around 16% to Rs 5,475 crore. Around 60% of domestic growth came from volume expansion and new-product launches, comprising 40% from volume and 20% from new products. Sun Pharma launched five products in India during the quarter and outpaced the Indian Pharmaceutical Market through volume growth, new launches, field-force expansion and brand building.

Management expects further semaglutide market-share gains, aided by in-house API and formulation capabilities and secured device-component supplies. Sun Pharma became the number two generic semaglutide injectable player in India and is the only company offering an auto-injector.

US formulations and global specialty medicines

US revenue was Rs 4,042 crore and flat on a reported basis, but declined 9.7% in constant currency to US$427 million because of lenalidomide erosion and heightened competition in certain generic products. Five US generic products were launched during the quarter.

Global specialty sales rose around 13% year-on-year to US$351 million, with growth led by ILUMYA, Odomzo and CEQUA. Levulan's seasonality moderated innovative-medicine growth. Management said LEQSELVI had crossed 1,000 prescribers in June and that UNLOXCYT adoption was increasing across cancer centres and integrated health systems. Both products are expected to have future label-expansion opportunities.

Innovative R&D represented 30% of quarterly R&D spend of Rs 826 crore.

Profitability and Management Guidance

Q1 FY27 EBITDA increased around 5% year-on-year to Rs 4,296 crore, while the EBITDA margin declined 133 basis points year-on-year to 28%. Gross margin increased around 95 basis points to approximately 81%.

Reported net profit was around Rs 2,753 crore, up around 34% year-on-year. Adjusted net profit including forex gains was around Rs 3,019 crore, up around 5%. The quarter included Rs 167 crore of Organon acquisition-related costs.

Management expects the effective tax rate, which was 27.8%, to remain near current levels until the acquisition closes. Despite the strong first quarter, management retained its high-single-digit revenue-growth guidance for FY27.

Organon Acquisition and Integration Outlook

Management expects the Organon acquisition to close in Q4 FY27. Regulatory filings have been completed and integration planning is underway. The transaction is expected to provide Sun Pharma with exposure to biosimilars and innovative medicines in women's health and fertility.

ICICI Direct estimates that Sun Pharma will assume around US$9.25 billion to US$9.75 billion of Organon debt, assuming US$2 billion to US$2.5 billion is paid through internal accruals. This would result in pro-forma net debt to EBITDA of around 2.3 times.

The broker is concerned that only about one-third of the Organon portfolio—innovative medicines and biosimilars—is a growth engine. The combined entity must improve the remaining generics and established-products portfolio.

Valuation and Broker Forecasts

ICICI Direct's Rs 2,090 target price is based on a sum-of-the-parts valuation. The broker values Sun Pharma's base FY28E EBITDA of Rs 20,633 crore at 22 times and Organon's FY28E EBITDA of Rs 18,261 crore at 6 times, before deducting net debt of Rs 62,120 crore. The resulting implied market capitalisation is Rs 5,01,376 crore.

The FY28E estimates reflect the anticipated consolidation of Organon.

Key Risks

• Slower-than-expected ramp-up of Organon's innovative medicines portfolio.
• Slower-than-expected improvement in the generics-plus-established-products portfolio.
• Higher-than-expected acquisition-related costs or lower-than-expected revenue and cost synergies.
• Leverage arising from the Organon acquisition, which reduces the margin of safety.